Drugs / BGF MDI
BGF MDI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01980615 | Nov → Dec 2013 | — | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGF MDI | “The budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) is an inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist...” PMID 29544728 ↗ Mar 2018 |
| Known as | BGF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01980615 ↗ |
| Known as | budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler | “The Phase III KRONOS study (NCT02497001) found the fixed-dose combination triple therapy budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) to be...” PMID 33152467 ↗ Nov 2020 |
| Known as | budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler | “The budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) is an inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist...” PMID 29544728 ↗ Mar 2018 |
| Known as | PT010 | “Inhaled BGF (PT010) Dose 1” NCT01980615 ↗ |
| Route | Inhaled | “Inhaled BGF (PT010) Dose 1” NCT01980615 ↗ |